Medicare Prescription Plans Limit Access to Recommended Drugs for Clostridioides difficile Infection

Article Immunology

Impact of Revised Infectious Diseases Society of America and Society for Healthcare Epidemiology of America Clinical Practice Guidelines on the Treatment of Clostridium difficile Infections in the United States

Cornelius J. Clancy et al.

Summary: Following revised clinical practice guidelines, there was a significant increase in the cumulative treatment courses of oral vancomycin and fidaxomicin, while a decrease in the treatment courses of oral metronidazole in the US. Monthly use of vancomycin significantly increased, and metronidazole significantly decreased after the publication of revised guidelines. The impact of revised guidelines in changing treatment practices for CDI was greater than clinical trial data establishing the superiority of vancomycin over metronidazole.

CLINICAL INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Immunology

Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults

Stuart Johnson et al.

Summary: This clinical practice guideline is a focused update on the management of Clostridioides difficile infection (CDI) in adults, specifically addressing the use of fidaxomicin and bezlotoxumab. The recommendations from the multidisciplinary panel are based on evidence derived from systematic literature reviews, aiming to guide healthcare professionals caring for adults with CDI.

CLINICAL INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Medicine, General & Internal